ResearcherWuhan Union HospitalActive in the last 2 years
Xiaoli Lan
Matched on ORCID iD 0000-0002-7263-7399; OpenAlex author ID A5044715426, A5080642996. Sources: ClinicalTrials.gov.
Their work
- Papers
- 5
- Trials
- 5
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2020: 1 paper · 2021: 1 trial · 2022: 1 paper · 2023: 1 paper · 2024: 1 trial · 2025: 1 paper, 2 trials · 2026: 1 paper, 1 trial
Papers 5
- Engineering Goat Milk-Derived Extracellular Vesicles for Dual-Model Imaging and Anti-Inflammatory Photothermal Therapy of Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.5c01963↗
- Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Cancer Theranostics. Co-author DOI 10.1021/acs.molpharmaceut.5c01039↗
- Optical image-guided therapy of pancreatic cancer with an ultra-small bispecific protein. Co-author DOI 10.1007/s00259-023-06186-4↗
- Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Imaging. Co-author DOI 10.3390/pharmaceutics14091791↗
- Synthesis and Preclinical Evaluation of a 68Ga-Radiolabeled Peptide Targeting Very Late Antigen-3 for PET Imaging of Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.0c00416↗
Trials 5
- Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value… Study director NCT07552467↗
- Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors Study director NCT07301814↗
- The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors Study director NCT07651020↗
- Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors Study director NCT06843629↗
- 68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients Study director NCT05490849↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wenyu Song · 2 shared papers, 2023–2026 · strength 0.55
- Yongkang Gai · 3 shared papers, 2020–2025 · strength 0.49
- Paper Preclinical Development and Comparison of [99mTc]Tc/[177Lu]Lu-Labeled Anti-Trop2 Fc-Fused Nanobodies as Pancreatic Canc… DOI 10.1021/acs.molpharmaceut.5c01039↗
- Paper Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Im… DOI 10.3390/pharmaceutics14091791↗
- Paper Synthesis and Preclinical Evaluation of a 68Ga-Radiolabeled Peptide Targeting Very Late Antigen-3 for PET Imaging of Pa… DOI 10.1021/acs.molpharmaceut.0c00416↗
- Rui An · 1 shared paper, 2026 · strength 0.29
- Yang Gao · 1 shared paper, 2026 · strength 0.29
- Weibo Cai · 1 shared paper, 2023 · strength 0.26
- Dawei Jiang · 1 shared paper, 2025 · strength 0.23
- Feng Yuan · 1 shared paper, 2025 · strength 0.23
- Yaqun Jiang · 1 shared paper, 2022 · strength 0.15
- Huiling Li · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.